Eva Wolf1, Andreas Trein2, Axel Baumgarten3, Christoph Stephan4, Hans Jaeger1, Heribert Hillenbrand5, Siegfried Koeppe6, Thomas Lutz7, Bettina Koenig8, Hans-Juergen Stellbrink9. 1. HIV Research and Clinical Care Centre, MVZ Karlsplatz, Munich, Germany. 2. HIV Center (Drs A. Schaffert/E. Schnaitmann/A. Trein), Stuttgart, Germany. 3. HIV Practice (Drs S. Dupke/A. Baumgarten/A. Carganico), Berlin, Germany. 4. HIV Center, University Hospital Frankfurt, Goethe University, Frankfurt, Germany. 5. MVZ PraxisCityOst (Drs. H. Hillenbrand, H. Karcher), Berlin, Germany. 6. Gemeinschaftspraxis (Drs S. Koeppe/P. Kreckel), Berlin, Germany. 7. Infektiologikum Frankfurt-City, Frankfurt am Main, Germany. 8. Medical Department, AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany. 9. Study Center, Infektionsmedizinisches Centrum Hamburg, Hamburg, Germany.
Abstract
INTRODUCTION: STAR/STELLA is a prospective[TS1] cohort of HIV patients initiated on LPV/r-based ART in routine clinical practice. Here, virologic/immunologic outcomes and safety data of LPV/r-based first-line ART over a period of 144 weeks are presented. METHODS: Analysis included ART-naïve patients who started on LPV/r before July 2011 (i.e. patients with ≥144 weeks since ART initiation). Safety evaluation included adverse events (AEs), discontinuations (disc.) due to AEs, and symptoms assessed with the self-report ACTG Symptom Distress Module (ASDM; high score=high distress). RESULTS: 1409 patients were included (84% men; 76% on TDF+FTC), with a large proportion in advanced stages of HIV disease at ART initiation: 48% had a CD4 count <200/µL, 55% had HIV RNA levels >100,000 c/mL. 53% of patients (n=746) remained on LPV/r for at least 144 weeks. Time on drug was longer for patients initiated before 2008 than in subsequent years (HRadj, 1.2; 95% CI, 1.0-1.4; p=0.04; hazard ratio adjusted for CD4 <200/µL and HIV RNA >100,000 c/mL). Main reasons for d/c were: AEs (19.3%), patient wish (9.2%), virologic/immunologic failure (4.1%), and noncompliance (2.8%); 1.6% of patients died. By week 144, 33% of patients had >750 CD4/µL (Kaplan-Meier estimate): time to CD4 count >750 c/ µL, stratified by BL CD4 count, is shown in Figure 1. CONCLUSION: In the STAR/STELLA observational cohort, LPV/r-based ART demonstrated good virologic outcomes and immune recovery in ART-naïve patients over 144 weeks, with significant improvements in symptom distress. Over three years, <5% of patients discontinued LPV/r due to virologic/immunologic failure, and 19% of patients discontinued for tolerability reasons.
INTRODUCTION:STAR/STELLA is a prospective[TS1] cohort of HIV patients initiated on LPV/r-based ART in routine clinical practice. Here, virologic/immunologic outcomes and safety data of LPV/r-based first-line ART over a period of 144 weeks are presented. METHODS: Analysis included ART-naïve patients who started on LPV/r before July 2011 (i.e. patients with ≥144 weeks since ART initiation). Safety evaluation included adverse events (AEs), discontinuations (disc.) due to AEs, and symptoms assessed with the self-report ACTG Symptom Distress Module (ASDM; high score=high distress). RESULTS: 1409 patients were included (84% men; 76% on TDF+FTC), with a large proportion in advanced stages of HIV disease at ART initiation: 48% had a CD4 count <200/µL, 55% had HIV RNA levels >100,000 c/mL. 53% of patients (n=746) remained on LPV/r for at least 144 weeks. Time on drug was longer for patients initiated before 2008 than in subsequent years (HRadj, 1.2; 95% CI, 1.0-1.4; p=0.04; hazard ratio adjusted for CD4 <200/µL and HIV RNA >100,000 c/mL). Main reasons for d/c were: AEs (19.3%), patient wish (9.2%), virologic/immunologic failure (4.1%), and noncompliance (2.8%); 1.6% of patients died. By week 144, 33% of patients had >750 CD4/µL (Kaplan-Meier estimate): time to CD4 count >750 c/ µL, stratified by BL CD4 count, is shown in Figure 1. CONCLUSION: In the STAR/STELLA observational cohort, LPV/r-based ART demonstrated good virologic outcomes and immune recovery in ART-naïve patients over 144 weeks, with significant improvements in symptom distress. Over three years, <5% of patients discontinued LPV/r due to virologic/immunologic failure, and 19% of patients discontinued for tolerability reasons.